Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
| Autor: | Devinder Gill, E. Van Den Neste, B. Glass, Dc Linch, Christian Gisselbrecht, Noel-Jean Milpied, Catherine Thieblemont, John Radford, Craig H. Moskowitz, Marek Trneny, David D.F. Ma, Ofer Shpilberg, Gilles Salles, Jean Briere, Nicolas Ketterer, Nicolas Mounier, Norbert Schmitz, Ulrich Dührsen |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent Medizin Salvage therapy Aggressive lymphoma Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation International Prognostic Index Recurrence Internal medicine medicine Refractory Diffuse Large B-Cell Lymphoma Humans Autografts Survival rate Aged Salvage Therapy Transplantation business.industry Hematology Middle Aged medicine.disease Surgery Survival Rate 030220 oncology & carcinogenesis Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma 030215 immunology Stem Cell Transplantation |
| Zdroj: | Bone marrow transplantation. 51(1) |
| ISSN: | 1476-5365 |
| Popis: | Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink